



Review

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors

ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration



Andrew DJ. Pearson ^{a,*}, Carl Allen ^{b,c,1}, Jason Fangusaro ^{d,e,1},
 Caroline Hutter ^{f,g,1}, Olaf Witt ^{h,i,j,1}, Susan Weiner ^k, Gregory Reaman ^l,
 Mark Russo ^m, Pratiti Bandopadhyay ^{n,o}, Sama Ahsan ^p, Amy Barone ¹,
 Elly Barry ^q, Teresa de Rojas ^a, Michael Fisher ^r, Elizabeth Fox ^s,
 Julia Glade Bender ^t, Lia Gore ^{u,v}, Darren Hargrave ^w, Doug Hawkins ^{x,y},
 Brent Kreider ^z, Abraham J. Langseth ^{aa}, Giovanni Lesa ^{ab},
 Franca Ligas ^{ab}, Marcelo Marotti ^{ac}, Lynley V. Marshall ^{ad,ae},
 Kahina Nasri ^{af}, Koen Norga ^{ag,ah,ai}, Karsten Nysom ^{aj}, Alberto Pappo ^s,
 Gianluca Rossato ^{ak}, Nicole Scobie ^{al}, Malcolm Smith ^{am},
 Elliot Stieglitz ^{an}, Brenda Weigel ^{ao}, Amy Weinstein ^{ap}, Ruth Viana ^{aq},
 Dominik Karres ^{ab}, Gilles Vassal ^{a,ar}

^a ACCELERATE, Europe

^b Texas Children Hospital, Houston, TX, USA

^c Baylor College of Medicine, Houston, TX, USA

^d Children's Healthcare of Atlanta, USA

^e Emory University School of Medicine, Atlanta, USA

^f St. Anna Children's Hospital, Vienna, Austria

^g Children's Cancer Research Institute, Vienna, Austria

^h Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany

ⁱ Heidelberg University Hospital, Heidelberg, Germany

^j German Cancer Research Center, Heidelberg, Germany

^k Children's Cancer Cause, Washington DC, USA

^l US Food and Drug Administration, Silver Springs, USA

^m Novartis, New Jersey, USA

ⁿ Department of Pediatrics, Harvard Medical School, Broad Institute, USA

* Corresponding author:

E-mail address: andy1pearson@btinternert.com (A.DJ. Pearson).

¹ Joint first authors.

- ^o Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA
^p Merck & Co., Inc, Rahway, NJ, USA
^q Day One Biopharmaceuticals, San Francisco, USA
^r The Children's Hospital of Philadelphia, Philadelphia, USA
^s St Jude Children's Research Hospital, Tennessee, USA
^t Memorial Sloan Kettering Cancer Centre, New York, USA
^u Children's Hospital Colorado, USA
^v University of Colorado, USA
^w UCL Great Ormond Street Institute of Child Health, London UK
^x Seattle Children's Hospital, USA
^y Children's Oncology Group, Seattle, USA
^z BioMed Valley Discoveries, Kansas City, MO, USA
^{aa} SpringWorks Therapeutics, Stamford, CT, USA
^{ab} Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands
^{ac} Boehringer Ingelheim, Germany
^{ad} The Royal Marsden Hospital, London, UK
^{ae} The Institute of Cancer Research, London, UK
^{af} Pierre-Fabre, Paris, France
^{ag} Antwerp University Hospital, Antwerp, Belgium
^{ah} Paediatric Committee of the European Medicines Agency, (EMA), Netherlands
^{ai} Federal Agency for Medicines and Health Products, Brussels, Belgium
^{aj} Rigshospitalet, Copenhagen, Denmark
^{ak} F. Hoffmann-La Roche AG, Basel, Switzerland
^{al} Zoe4Life, Sullens, Switzerland
^{am} National Cancer Institute, Maryland, USA
^{an} UCSF Benioff Children's Hospital San Francisco, USA
^{ao} University of Minnesota, Minneapolis, USA
^{ap} Pediatric Brain Tumor Foundation, Atlanta, USA
^{aq} Alexion Pharmaceuticals, Zurich, Switzerland
^{ar} Gustave Roussy Cancer Centre, Paris, France

Received 14 July 2022; received in revised form 8 September 2022; accepted 26 September 2022

Available online 14 October 2022

KEYWORDS

Paediatric oncology;
 MAPK pathway
 inhibitors;
 Paediatric strategy
 forum;
 Drug development;
 Cancer therapeutics

Abstract As the mitogen-activated protein kinase (MAPK) signalling pathway is activated in many paediatric cancers, it is an important therapeutic target. Currently, a range of targeted MAPK pathway inhibitors are being developed in adults. However, MAPK signals through many cascades and feedback loops and perturbing the MAPK pathway may have substantial influence on other pathways as well as normal development. In view of these issues, the ninth Paediatric Strategy Forum focused on MAPK inhibitors.

Development of MAPK pathway inhibitors to date has been predominantly driven by adult indications such as malignant melanoma. However, these inhibitors may also target unmet needs in paediatric low-grade gliomas, high-grade gliomas, Langerhans cell histiocytosis, juvenile myelomonocytic leukaemia and several other paediatric conditions. Although MAPK inhibitors have demonstrated activity in paediatric cancer, the response rates and duration of responses needs improvement and better documentation. The rapid development and evaluation of combination approaches, based on a deep understanding of biology, is required to optimise responses and to avoid paradoxical tumour growth and other unintended consequences including severe toxicity. Better inhibitors with higher central nervous system penetration for primary brain tumours and cancers with a propensity for central nervous system metastases need to be studied to determine if they are more effective than agents currently being used, and the optimum duration of therapy with MAPK inhibition needs to be determined.

Systematic and coordinated clinical investigations to inform future treatment strategies with MAPK inhibitors, rather than use outside of clinical trials, are needed to fully assess the risks and benefits of these single agents and combination strategies in both front-line and in the refractory/relapse settings. Platform trials could address the investigation of multiple similar products and combinations. Accelerating the introduction of MAPK inhibitors into front-line paediatric studies is a priority, as is ensuring that these studies generate data appropriate for scientific and regulatory purposes. Early discussions with regulators are crucial,

particularly if external controls are considered as randomised control trials in small patient populations can be challenging.

Functional end-points specific to the populations in which they are studied, such as visual acuity, motor and neuro psychological function are important, as these outcomes are often more reflective of benefit for lower grade tumours (such as paediatric low-grade glioma and plexiform neurofibroma) and should be included in initial study designs for paediatric low-grade glioma. Early prospective discussions and agreements with regulators are necessary.

Long-term follow-up of patients receiving MAPK inhibitors is crucial in view of their prolonged administration and the important involvement of this pathway in normal development.

Further rational development, with a detailed understanding of biology of this class of products, is crucial to ensure they provide optimal benefit while minimising toxicity to children and adolescents with cancer.

© 2022 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Activating somatic mutations of the mitogen-activated protein kinase (MAPK) pathway are frequently associated with paediatric tumours and malignancies where there are currently unmet needs [3,4,12]. The *BRAF* V600E mutation occurs in approximately 7% of all human cancers [5]. A range of targeted MAPK pathway inhibitors has been developed, evaluated and approved in adult malignancies such as malignant melanoma [6], G12C mutation positive non-small cell lung cancer [7] and colorectal cancer [8], but only one inhibitor (Koselugo[®] [selumetinib]) has received specific regulatory approval in children [9–12]. RAF inhibitors have demonstrated activity in paediatric low-grade gliomas (pLGG) [13–16], paediatric high-grade gliomas (pHGG) [17,18], Langerhans cell histiocytosis (LCH) [19] and select solid tumours [20]. MEK inhibitors have also been active in plexiform neurofibroma [9–12], pLGG [21,22], LCH [23] and some subtypes of leukaemia/juvenile myelomonocytic leukaemia (JMML) [24], but definitive activity in other paediatric tumours has not been clearly demonstrated. The complexity and differences in the (epi)genomic landscape of different childhood tumours likely predict this variation in response to MAPK pathway (RAS, MEK, ERK) inhibition with targeted agents [4].

In view of the importance of the MAPK pathway in paediatric tumours and malignancies and the number of targeted pathway inhibitors currently being evaluated in adults and children, it was considered timely to hold a Paediatric Strategy Forum to focus on the role of these inhibitors in children. The Forum was organised by ACCELERATE [25,26] in collaboration with the European Medicines Agency (EMA) with the participation of the Food and Drug Administration (FDA) and built on the format and ethos of previous Forums aiming to evaluate science, facilitate dialogue and share information [27–33].

The Paediatric Strategy Forum focused on the key issues in the ongoing development of inhibitors of the MAPK pathway in paediatric oncology. Specifically, it addressed: (i) What are the unmet needs with existing MAPK pathway inhibitors?; (ii) How to better utilise existing MAPK pathway inhibitors (duration, schedule, alone or in combinations)?; (iii) What are the best end-points for MAPK pathway inhibitor trials for different indications?; (iv) Can predictive biomarkers for treatment response and resistance be identified to answer these questions and answers? The Forum also highlighted the crucial importance of formulation and different pharmacokinetic and pharmacodynamic properties, including central nervous system (CNS) penetration and short- and long-term toxicities of these targeted agents.

The meeting was held virtually on 28 and 29 March 2022 with 206 participants: 98 international paediatric oncology experts from Europe, US, Canada, Australia, South America, Japan and India; 47 representatives from ten pharmaceutical companies in Europe and the US (Alexion/AstraZeneca, BioMed Valley Discoveries, Boehringer-Ingelheim, Day One Biopharmaceuticals, Merck & Co., Inc. Rahway, NJ, USA, Novartis Pierre Fabre, Roche, SpringWorks Therapeutics); 14 patient advocates from Europe, the US and Canada (representatives from Andrew McDonough B⁺ Foundation, Children's Cancer Cause, Coalition Against Childhood Cancer, Histiocure Foundation, Histiocytosis Association, Imagine for Margo, NGO Karkinaki Awareness for Childhood and Adolescent Cancer, Paediatric Brain Tumour Foundation, Solving Kids' Cancer, Solving Kids' Cancer UK, Swedish Childhood Cancer Fund, Zoé4life and Childhood Cancer International–Europe); 25 regulators from the EMA (including the Paediatric Committee [PDCO]) and national competent authorities within the EU regulatory network, European Health Technology Assessment [HTA] bodies, US FDA and Health Canada as observers;

the ACCELERATE Operations Coordinator. An overview of the biology of the MAPK pathway and a review of the current trials, plans and unmet needs in pLGG, pHGG, LCH and leukaemia were presented by academic experts. The details of seventeen inhibitors of the MAPK pathway were presented by industry representatives. The Forum concluded with the patient advocate perspectives and a multi-stakeholder strategic discussion.

2. Biology of the MAPK pathway

The MAPK signalling cascade is commonly altered in cancer and is crucial in normal development [1–3]. MAPK signalling also impacts many other pathways and feedback loops, especially the PI3K/AKT/mTOR pathway (Fig. 1). Therefore, perturbing the MAPK pathway may have substantial influence on other pathways.

The MAPK pathway is frequently activated through somatic events across a number of paediatric cancers, including JMML [34], acute myeloid leukaemia (AML) pLGG [35–37], pHGG [39,40], LCH [41], sarcoma, fusion-negative rhabdomyosarcoma [42], neuroblastoma [43] and osteosarcoma [2,3,44]. Neurofibromatosis type 1 (NF1), the most frequent hereditary cancer predisposition syndrome associated with MAPK pathway activation, is a genetic disease characterised by having a heterozygous pathogenic *NF1* variant [45]. Neurofibromin (encoded by the *NF1* gene) negatively regulates RAS activation [46]. The most common NF1-associated tumours include LGG, HGG, plexiform neurofibromas and malignant peripheral nerve sheath tumours [47].

pLGG is an example of a disease of aberrant MAPK signalling with *BRAF* being the most frequently altered gene. In most tumours, there is only one driver event, which is most commonly a structural variant that leads to pathway activation; less frequently, oncogenic *BRAF* point mutations occur [35–38]. The most common

BRAF rearrangement results in loss of the N' terminal negative regulatory domain and replacement by another gene, most commonly *KIAA1549*, with the fused gene resulting in an activated BRAF kinase [35–40]. The next most frequent alteration is the *BRAFV600E* hotspot mutation which results in constitutive activation of the BRAF kinase. Alterations in the FGFR family represent the second most common group of somatic alterations and affect *FGFR1* or *FGFR2* [48]. Alterations in the *FGFR1* gene include tandem duplications, point mutations and fusions. Tumours with *FGFR1* point mutations frequently have co-occurring point mutations that are predicted to activate the MAPK or mTOR signalling pathway, which often include *PTPN11*, *PIK3CA* or loss-of-function *NF1* alterations. In addition, oncogene-induced senescence (robust and sustained anti-proliferative response brought about by oncogenic signalling resulting from an activating mutation of an oncogene, or the inactivation of a tumour-suppressor gene [49]) and its associated secretory phenotype, as well as the tumour microenvironment, are important modulators of tumour growth, behaviour and response to therapy.

Kinase inhibitors have been successful in the therapy of malignant melanoma, including BRAF, MEK and ERK inhibitors targeting the MAPK pathway; PI3K, AKT or mTOR inhibitors targeting the PI3K pathway and some newer FGFR inhibitors are in development [50]. However, it is essential to understand the biology of these oncogenic pathways, as there are risks of paradoxical signalling activation via feedback loops with targeting of some nodes. For example, preclinical studies of *BRAF* V600E-mutated pLGG cell lines treated with a type 1 BRAF inhibitor are effective in switching off MAPK signalling, while treatment with the same BRAF inhibitor in *BRAF KIAA1549*-rearranged cells can cause paradoxical pathway activation




Fig. 1. MAPK, PI3K and mTOR pathways.

and an increase in cell growth [51]. Paradoxical activation of MAPK signalling led to unexpected tumour growth in a clinical trial evaluating the kinase inhibitor sorafenib for children with pLGGs, leading to early termination of the clinical trial [52].

The highly conserved MAPK pathway plays a critical role in the regulation of normal development across a large range of cell and tissue types, including (but not limited to) placental development, immune differentiation, angiogenesis, cardiovascular development and neurogenesis [53,54]. In the developing brain, MEK expression is essential for the regulation of gliogenesis [55]. Conversely, the loss of MEK1 is embryonic lethal due to anomalies in placental development, while the combined loss of MEK1 and MEK2 is also incompatible with postnatal survival, with effects across several tissues. Similarly, the loss of specific RAS and RAF isoforms in knock-out mice are also associated with an array of developmental defects [56]. While the effects of MAPK signalling in development have been widely evaluated, the sequelae of MAPK inhibition and thus long-term effects on childhood development remain unknown.

In summary: (i) the MAPK pathway is one of the most commonly altered pathways across childhood cancers; (ii) drugs targeting different components of the pathway may enable precision medicine approaches; (iii) a deeper understanding of the biology of the pathway is required to prevent potential for paradoxical cancer cell growth and to select the patient populations most likely to benefit from treatment and to avoid toxicity.

2.1. MAPK pathway inhibitors in pLGG

Approximately 3500 patients present with pLGG per year in North America and Europe. Currently, 90% of these patients survive with 50% cured by surgery alone [57]. However, the 5-year progression-free survival (PFS), after chemotherapy, is less than 50% with many patients receiving multiple lines of therapies in an attempt to avoid radiotherapy and associated substantial long-term sequelae [58,59]. The World Health Organisation classification of pLGG is evolving with the inclusion of molecular data rather than simple morphological grading [60]. pLGG is one of the six paediatric malignancies in the World Health Organisation Global Childhood Cancer Initiative to be addressed to save one million lives of children with cancer by 2030 [61]. **The current unmet needs** in pLGG are to minimise morbidity and to maximise quality of life by replacing chemotherapy with presumably less toxic, more effective targeted therapy. In addition to overall survival and PFS, new clinical end-points have also been proposed by international cooperative groups for inclusion in trial designs. These include visual acuity, quality of life, motor and neuropsychological functioning since the majority of these children will survive well into adulthood yet may suffer significant risk for reduced quality of life and compromise function in these realms. The ongoing and completed trials of inhibitors of the MAPK pathway in pLGG are shown in [Tables 1 and 2](#). The inhibition of MEK results in partial responses ($\geq 50\%$

Table 1
Summary of ongoing trials in newly diagnosed/recurrent pLGG with MAPK pathway inhibitors.

Trial	Study start	Population	Intervention
Newly diagnosed disease			
Tadpole G (NCT02684058) [16,68]	2017	Newly diagnosed <i>BRAF</i> V600E-mutant pLGG	Randomised phase 2 - dabrafenib (BRAFi) + trametinib (MEK1/2i) versus carboplatin and vincristine
COG ACNS1831 (NCT03871257) [106]	2019	Untreated <i>NFI</i> -associated pLGG	Phase 3 - carboplatin + vincristine versus selumetinib (MEK1/2i)
COG ACNS1833 (NCT04166409) [107]	2020	Untreated non- <i>NFI</i> and non- <i>BRAF</i> V600E mutant pLGG	Phase 3 - carboplatin + vincristine versus selumetinib (MEK1/2i)
LOGGIC (In Preparation)		Newly diagnosed non- <i>NFI</i> mutant pLGG patients who need further treatment after initial operation	Phase 3 - MAPK inhibitor versus physician's choice
MEKTRIC (NCT05180825) [108]	2022	Newly diagnosed non- <i>NFI</i> , <i>BRAF</i> wild-type pLGGs	Randomised phase 2 - trametinib(MEK1/2i) versus weekly vinblastine
Recurrent or Progressive disease			
PNOC026/DAY101-001/FIREFLY-1 (NCT04775485) [109]	2021	Recurrent or progressive <i>BRAF</i> -mutant pLGG	Phase 2 - Tovorafenib [DAY101] (Pan-RAFi)
PBTC-055 (NCT04201457) [71]	2019	Recurrent or progressive <i>BRAF</i> -mutant pLGG or pHGG	Phase 1/2 - dabrafenib (BRAFi), trametinib (MEK1/2), hydroxychloroquine
COG ACNS1931 (NCT04576117) [110]	2021	Recurrent or Progressive pLGG	Phase 3 - selumetinib versus selumetinib + vinblastine (MEK1/2i)
Paediatric MATCH (NCT03155620) [111]	2017	Ras/Raf pathway activated tumours	Phase 1/2 - ulixertinib (ERK1/2i)
Phase I/II MEK162 Ras/Raf Pathway Activated Tumours (NCT02285439) [112]	2016	Ras/Raf pathway activated tumours	Phase 1/2 - MEK162
SJ901 (NCT04923126) [113]	2021	Recurrent or progressive pLGG	Phase 1/2 - mirdametinib (MEK1/2i)
PNOC021 (NCT04485559) [114]	2020	Recurrent or Progressive pLGG	Phase 1 - trametinib (MEK1/2i) and everolimus

Table 2

Summary of completed trials in recurrent pLGG with MAPK pathway inhibitors (no trials in newly diagnosed pLGG).

Trial	Date Study start and end	Population	Intervention
Recurrent or Progressive disease			
PNOC014 ^a (NCT03429803) [15,115]	2018–2024	Recurrent or progressive solid or CNS tumours with activated RAS/RAF/MEK/ERK pathway	Phase 1 – DAY101
PBTC-029 ^a (NCT01089101) [21,116]	2010–2025	Recurrent or refractory pLGG	Phase 1/2 - Selumetinib
NYU 10–00561 ^b (NCT01338857) [52,117]	2011–2013	Recurrent or progressive LGG (including NF-1)	Phase 2 - Sorafenib
Novartis 116540 ^c (NCT02124772) [118]	2015–2020	Recurrent or refractory malignancies with V600 mutations	Phase 1/2 – Trametinib alone or trametinib plus dabrafenib

^a Active, not recruiting (i.e., study end date is the projected primary completion date).

^b Terminated - ineffective.

^c Completed.

tumour reduction by RANO criteria) in 30–40% of recurrent pLGG [21,22,62], and similar results have been obtained with BRAF inhibitors in BRAF V600-mutated pLGG [6,13,18] and BRAF/MEK combinations [16]. A randomised trial in BRAF V600–mutant pLGG has demonstrated superior overall response rate, clinical benefit rate and median PFS with dabrafenib and trametinib compared to carboplatin and vincristine [16]. However, not all patients remain in continuous partial response after stopping therapy and tumour rebound may occur following treatment cessation. Both better inhibitors, with, for example, higher CNS penetration and better combination therapies, are likely required to drive deeper and more durable responses. However, inhibitors with higher CNS penetration need to be studied to determine if they are more effective than agents currently being used. In addition, tumour microenvironmental factors including senescence-related pathways likely modulate treatment response to MAPK inhibitors and may provide opportunities for novel single agent and combination therapies [63–65]. With increasing understanding of disease biology, it is appreciated that pLGGs are very heterogeneous tumours [66], most clearly depicted in the difference between those pLGG arising in patients with NF1 compared to the rest of the population. This molecular heterogeneity demands that predictive biomarkers are discovered and understood to better select specific patients for tailored therapy. Understanding rebound and resistance are key future goals. At present, the optimal duration of therapy is unknown with response persisting in some patients after drug discontinuation whilst others experience tumour regrowth or progression. The current pragmatic approach is to treat clinical benefit until loss of clinical benefit or for a certain specific duration (typically approximately 2 years) and then stopping therapy. In view of the prolonged administration, the involvement of this pathway in normal development and the life expectancy of patients into adulthood, a better understanding of the late effects of patients receiving MAPK inhibitors is required. Ancillary and integrated biological studies will hopefully allow the understanding of which patients require further therapy. Currently,

there are several studies open or in the late stages of planning for both newly diagnosed and recurrent pLGG and completed studies (Tables 1 and 2). For the future, an industry-supported, academic-sponsored international platform trial that provides clinical trial data that can be used for licensing purposes and with early input from regulators, could address the investigation of multiple similar products and combinations in small patient populations. Within the same overall trial structure, products from different pharmaceutical companies and different mechanisms of action could be evaluated using an adaptive design and products for further evaluation could be identified.

2.2. MAPK pathway inhibitors in pHGG

Approximately 1150 patients present each year in North America and Europe with pHGG. Similar to pLGG, the classification of pHGG is evolving with inclusion of molecular data rather than simple morphohistological grading [60]. BRAF V600E mutations occur in approximately 6% of pHGG (70 patients per year in Europe and North America) (mostly midline or hemispheric tumours) and confer a better prognosis [39,67] with 67% 5-year PFS with conventional chemotherapy and radiotherapy [39]. **The current unmet needs in BRAF-mutated pHGG** are to identify more effective therapies that would increase survival and in the long-term, ultimately, to reduce or avoid radiation therapy entirely. In one study, BRAF inhibition with dabrafenib resulted in a maximum tumour reduction of $\geq 50\%$ in 68% of patients with pHGG, but this was of short duration (median PFS 7.4 months) [13]. Combination approaches are required, and studies are planned or ongoing of BRAF and MEK inhibitors (dabrafenib + trametinib [NCT02684058 [68], NCT03919071 [69]], binimetinib + encorafenib [≥ 18 years] [NCT03973918 [70]], dabrafenib + trametinib + hydroxychloroquine [NCT04201457 [71]]). In newly diagnosed and recurrent pHGG, there has been a retrospective, multi-institutional review of patients with BRAF-mutant pHGG treated off-label with BRAF inhibitors with or without MEK inhibitors, confirming activity [72].

Responses were observed and the authors concluded that adjuvant randomised trials of BRAF inhibitors in adult and paediatric low-grade and high-grade gliomas were needed. Similarly to LGG, inhibitors with higher CNS penetration need to be evaluated. The key future focus is to improve overall survival of these patients by determining optimal inhibitor combinations and ascertain if treatment response/resistance [40,73] depends on blood brain barrier penetrance, secondary mutations, tumour morphology or other specifics of the tumour's molecular landscape.

2.3. MAPK pathway inhibitors in plexiform neurofibromas in NF1

Approximately 66,000–110,000 individuals in the US have NF1 [74]. They have a 30–50% risk of developing plexiform neurofibromas (20,000–55,000) [47]. In a condition where previously effective medical therapies were lacking, treatment with the MEK inhibitor, selumetinib, has resulted in 68% of patients achieving a confirmed partial response (tumour volume decreases from baseline of $\geq 20\%$ by volumetric analysis of the MRI); 82% of these having a durable response (>1 year). The median time to initial response is 8 cycles (32 weeks) (range, 4 to 20) with a median time to best response being 16 cycles (range, 4 to 36) [9–11]. Selumetinib (Koselugo[®]) as monotherapy is indicated for the treatment of paediatric patients 2 years of age and older in the United States (and 3 years of age and older in the European Union) with NF 1 who have symptomatic, inoperable plexiform neurofibromas [12]. Mirademetinib is an investigational agent which has been shown to be active in adolescents and adults with plexiform neurofibromas [75]. Preliminary data suggests plexiform neurofibromas respond to other MEK inhibitors as well [76]. **The current unmet needs** are to increase the number of patients who achieve partial response (as defined above), to obtain greater tumour volume reduction (as currently there are very few tumours which shrink more than 30%), to make responses more durable (most tumours regrow after stopping treatment), and to define schedules, e.g. intermittent dosing that reduce toxicity while maintaining efficacy with improved functional and quality of life outcomes, e.g. motor function and tumour-related pain. MAPK, including KRAS inhibitors, with better safety and efficacy profiles, used as monotherapy or in combination may also have a role.

2.4. MAPK pathway inhibitors in LCH

Approximately 800 children present each year in North America, Europe and Australia with LCH, which is similar in incidence to paediatric Hodgkin lymphoma and AML. LCH is therapeutically classified either as low-risk single system, low-risk multisystem and high-

risk multisystem disease (classically involving spleen, bone marrow and/or liver) with response to initial chemotherapy guiding further treatment for patients with multi-focal disease [77]. Generally, overall survival is very good (85% at 5 years for high-risk disease) [78] but disease eradication is achieved in $<50\%$ of patients with front-line therapy, and further attempts at curative therapy result in increased risk of morbidity and mortality [79]. LCH-neurodegenerative syndrome (dysarthria, dysmetria, learning and behaviour difficulties, and brain MRI changes) occurs in 5–10% of patients and currently does not have an effective therapy [80]. Conversely, some patients with low-risk disease may be over treated with conventional chemotherapy. **The current unmet needs** are to eliminate the risk of death in high-risk patients, improve treatment efficacy, reduce morbidity from treatment failure and/or chronic therapy and prevent and/or effectively treat LCH-neurodegenerative syndrome. Activating somatic MAPK pathway mutations are identified in almost all cases of LCH, with BRAF V600E as the most common, followed by activating mutations in MAP2K1 (which encodes MEK1). Alternative BRAF mutations, tyrosine kinase receptor gene mutations and ARAF mutations have also been reported [81]. BRAF inhibitors have been used off label in about 100 patients in international observational cohorts receiving vemurafenib or dabrafenib [19,82]. MAPK inhibitors are very efficient in achieving rapid clinical remission in LCH, and resistance to therapy is extremely rare [82]. However, there are high rates ($>75\%$) of rapid reactivation/progression with cessation of MAPK pathway inhibitors [82]. Molecular remission is not obtained with monotherapy as evaluated by high sensitivity peripheral blood or bone marrow studies [82–84] and additional or combination therapy is likely needed to eradicate subsets of mutated cells. A combination of BRAF and MEK inhibitors (trametinib with dabrafenib) has been evaluated [85]. New therapeutic approaches are needed for three situations: high-risk disease, LCH–neurodegenerative syndrome and low-risk recurrent LCH. A possible therapeutic schema is initial treatment with MAPK pathway inhibition, then chemotherapy followed by further MAPK pathway inhibition. The optimum duration of therapy with MAPK inhibition needs to be determined. There is a need for the systematic development of treatment strategies including MAPK inhibitors rather than the current widely spread off-label use in order to assess the risks and benefits of various agents and combination strategies for front-line and salvage settings. An inter-continental trial in high-risk disease could generate knowledge. Given the current evidence, it is crucial that MAPK inhibitors move forward into front-line and studies are appropriately designed and conducted to generate data suitable to support regulatory evaluation and approval.

2.5. MAPK pathway inhibitors in leukaemia

Approximately 150 children present each year in North America and Europe with JMML, where an excessive production of the monocytes infiltrate other organs including the spleen, liver, lung and gastrointestinal tract. Currently, allogeneic haematopoietic stem cell transplant is considered the only curative treatment and is usually delivered following antecedent chemotherapy for cytoreduction and disease control. Virtually, all patients with JMML have a MAPK pathway mutation [34]. In ADVL1521 (Phase II study of MEK inhibition with trametinib in children with relapsed or refractory JMML) (NCT03190915 [86]), 5 of 10 patients enrolled have had an objective response (1 complete response, 4 partial responses) and 2 patients have had prolonged stable disease [24]. However, no molecular responses as evidenced by decreased RAS pathway mutational burdens have been recorded in treated patients. A subsequent trial in North America, TACL2020-004, (in planning) will risk-stratify patients with newly diagnosed JMML to therapy based on genotyping and methylation analysis. Lower-risk patients [1 mutation and low DNA methylation] will receive azacitidine and trametinib. Higher-risk patients [>1 mutation and intermediate or high methylation] will receive azacitidine and trametinib, chemotherapy and allogeneic transplant. If successful, this approach may allow for a paradigm shift in ‘definitive therapy’ for these children with high-risk disease.

In acute lymphoblastic leukaemia, the most common childhood cancer, 30–50% of children have a subclonal mutation in the MAPK pathway [87,88]. RAS mutations can appear or disappear from diagnosis to relapse,

and their prognostic significance remains unknown. Patients with RAS mutations have a higher risk/incidence of CNS relapse, so this is an area of medical need. The ongoing SeluDex trial (NCT03705507) [89] is evaluating the role of MEK inhibition with selumetinib in combination with dexamethasone in relapsed or refractory acute lymphoblastic leukaemia [89,90]. Recruitment to this trial has proven challenging in the present era of available chimeric antigen-receptor T-cell therapy, commercially or clinical trials [90]; however, responses have been noted and the early reports show reasonable tolerability and feasibility. Finally, 43% of paediatric patients with AML have a MAPK pathway mutation at diagnosis [91]. It has been reported that RAS mutation variant allele frequency often increases at relapse, suggesting a role as a driver or disease modifier. Combination approaches of a MEK inhibitor and chemotherapy are under consideration for a clinical trial in children with RAS-mutant AML.

3. Products discussed at the Forum and Paediatric Investigation Plans and Written Requests

Seventeen medicinal products (selumetinib (Koselugo[®]), dabrafenib (Tafinlar[®]), trametinib (Mekinist[®]), vemurafenib (Zelboraf[®]), cobimetinib (Cotellic[®]), encorafenib (Braftovi[®]), binimetinib (Mektovi[®]), tovorafenib [DAY101], belvarafenib, pimasertib, ulixertinib, BI 1701963, BI 3011441, BI 1823911, GDP pan-KRAS inhibitor, mirdametinib and BGB-3245 were discussed at the Forum (Table 3).

As of March 2022, there were 7 published Paediatric Investigation Plans (PIP) agreed for selumetinib

Table 3
MAPK inhibitor medicinal products discussed at the Paediatric Strategy Forum.

Product	Target	Adult Marketing Authorisation	Paediatric Marketing Authorisation	Paediatric Investigation Plan	Company
Selumetinib (Koselugo [®])	MEK1/2	+	+	+	Alexion/AstraZeneca/Merck & Co., Inc., Rahway, NJ
Dabrafenib (Tafinlar [®])	BRAF	+		+	Novartis
Trametinib (Mekinist [®])	MEK1/2	+		+	Novartis
Vemurafenib	BRAF	+		Full waiver	Roche
Cobimetinib (Cotellic [®])	MEK1/2	+		+	Roche
Encorafenib (Braftovi [®])	BRAF	+		+	Pierre Fabre.
Binimetinib (Mektovi [®])	MEK1/2	+		+	Pierre Fabre.
Tovorafenib [DAY101]	Pan-RAF			+	Day One Biopharmaceuticals
Belvarafenib	Pan-RAF			–	Roche
Pimasertib	MEK			–	Day One Biopharmaceuticals
Ulixertinib	ERK1/2			–	BioMed Valley Discoveries
BI 1701963	SOS1::KRAS				Boehringer-Ingelheim
BI 3011441	MEK1/2			–	Boehringer-Ingelheim
BI 1823911	KRAS ^{G12C}			–	Boehringer-Ingelheim
GDP pan-KRAS inhibitor	Pan-KRAS			–	Boehringer-Ingelheim
Mirdametinib	MEK1/2			–	SpringWorks Therapeutics
BGB-3245	Pan-RAF			–	MapKure [joint venture of Spring Works/BeiGene]

(Koselugo[®]), dabrafenib (Tafinlar[®]) and trametinib (Mekinist[®]), cobimetinib (Cotellic[®]), encorafenib (Braftovi[®]) and binimetinib (Mektovi[®]) and tovorafenib (DAY101). Two of these PIPs are for combination therapy (dabrafenib + trametinib; encorafenib + binimetinib). The indications of the PIPs are disease-specific: melanoma with *BRAF* V600 mutations (n = 3); thyroid cancer (n = 1); NF-1 (plexiform neurofibroma) (n = 1); glioma with *BRAF* V600 (n = 1); LGG with *BRAF* fusion (n = 1). Two indications are histology agnostic: solid tumours with *BRAF* V600 (1) and solid tumours with RAS/RAF/MEK pathway activation (2) (Table 4). The agreed initial PIP for vemurafenib (Zelboraf[®]) in adolescent patients for the treatment of melanoma was later modified into a Product Specific Waiver in all age groups in the same condition on the grounds of ‘clinical studies are not expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset’ [92].

4. Discussion

4.1. Patient advocates’ perspectives

Patient advocates were concerned about the potential adverse developmental impact and late toxic effects of MAPK pathway inhibitors. They believed it was essential that companies, academic researchers and regulators pay particular attention to late effects on children’s development as monotherapy, and especially, combination therapy trials are developed. Late effects of therapy in adults may not be considered as companies develop agents for adult malignancies, but it is essential that this risk is considered in children. Patient advocates feel a special urgency about children with brain tumours, who often already live their entire lives with neurological sequelae from disease and treatment, as their families struggle with their care both short- and long-term.

Advocates urged that researchers come together with industries and regulators, perhaps in a dedicated meeting, to create new functional outcome measures that should include neurocognitive and endocrine changes in addition to PFS. Advocates’ input in creating such measures will add considerable value.

Common challenges are emerging about how to evaluate MAPK inhibitors as research uncovers deeper biological understanding of pHGG, pLGG, LCH and leukaemia. Variability in response to MAPK inhibitors shines a spotlight on the need for biomarkers to distinguish patients whose disease will respond differently. While patient advocates understand the challenges that small patient subsets create for trial design and patient recruitment, they support novel trial designs that are more finely tuned to the biology of patients’ disease profiles, e.g. platform and tumour agnostic trials, and the proposed JMML trial in which genotyping precedes disease classification and treatment. In

addition, advocates urged that no paediatric data be wasted and that clinicians analyse and make public data from off label and compassionate use that may yield fresh insights. Further, advocacy groups strongly endorsed and have helped financially support the conduct of international trials to address small patient populations, as exemplified in pLGG and LCH.

Multiple therapeutic opportunities make it even more important that tumour biology determines which agents are evaluated in children. Families and patients trust investigators and regulators, in collaboration with companies, to plan paediatric trials governed not only by what agents are available but also by the latest and best scientific insights. Any commitment to evaluating one specific therapy in a small patient population can effectively eliminate other potentially more promising opportunities for these patients.

5. General themes

5.1. Biology

Understanding specific tumour biology is critical, especially as the MAPK pathway is tightly connected to other signalling pathways. There may be unforeseen consequences if biology is not well understood, such as compensatory signalling up the regulation of alternative pathways and paradoxical tumour growth [51,52]. It is important to understand which feedback loops will be triggered by inhibiting one pathway and which other pathways could be co-inhibited for potentially synergistic effects. Furthermore, the importance of the MAPK pathway in normal development, especially glial differentiation, must be considered. The combinations of MAPK pathway inhibitors should be developed based on the mechanism of action, cancer biology and robust preclinical evaluation. The selection of combinations with compelling biological and clinical rationale for evaluation in children is essential given the rarity of paediatric cancers and the mismatch between the immense numbers of combinations that are available for testing compared to the number of clinical trials that can be conducted.

5.2. Trial design and regulatory considerations

Front-line academic trials of new products should be designed to generate data sufficient for regulatory decision making on benefit/risk assessment and there should be early discussion between academia, industry and regulators [26]. This is especially important if evaluating a new product is challenging in a randomised clinical trial. Trials submitted to fulfil regulatory requirements (e.g. PIPs and initial Paediatric Study Plans [iPSPs]) should be aligned with those designed prospectively by academic cooperative groups to be practice changing.

Table 4
Published PIPs agreed for MAPK inhibitors.

Product	Selumetinib (AZ/ Merck)	Dabrafenib + Trametinib (Novartis)	Dabrafenib mesylate (Novartis)	Trametinib dimethyl sulfoxide (Novartis)	Cobimetinib (Roche)	Vemurafenib (Roche)	Encorafenib + Binimetinib (Pierre Fabre)	DAY101 (DayOne)
PIP	Modified PIP Aug19 (EMA-001585-PIP01-13-M03)	PIP Oct20 (EMA-001147-PIP02-20 & EMA-001177-PIP02-20)	Modified PIP Oct20 (EMA-001147-PIP01-11-M07)	Modified PIP Oct20 (EMA-001177-PIP01-11-M06)	Modified PIP, Mar21 (EMA-001425-PIP01-13-M05)	Initial PIP decision in Aug16 2011. (EMA-000978-PIP01-10-M01) Modified 2016 Product Specific Waiver in melanoma”	Modified PIPs Mar18 - EMA-001588-PIP01-13-M01 & EMA-001454-PIP03-15-M01	PIP Dec20, EMA-002763-PIP01-20
MoA	MEK1, ERK1/2	BRAF + MEK1/2	BRAF	MEK1/2	MEK1	(B)RAF	BRAF inhibitor & MEK1/2 inhibitor	PanRAF kinase inhibitor
Condition	Melanoma, NF-1, thyroid cancer	Glioma	Melanoma, solid malignant tumours (excluding melanoma)	Melanoma, malignant neoplasms (except melanoma, haematologic, glioma)	Malignant neoplasms (except haematologic) with Ras, Raf or MEK pathway activation	Melanoma	Melanoma	Paediatric LGG
PIP Indication	NF1 - inoperable plexiform neurofibromas Selumetinib + radioactive iodine therapy for HR differentiated thyroid cancer	Glioma with BRAF V600 mutations	Melanoma with BRAF V600 activating mutations (adolescents) Solid tumours with BRAF V600 activating mutations (children)	Melanoma with BRAF V600 activating mutations (adolescent) Solid malignant tumour with known or expected RAS, RAF or MEK pathway activation (children)	Paediatric solid malignant tumour with Ras, Raf or MEK pathway activation, R/R	Melanoma in adolescents - waiver on the grounds of “clinical studies not expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset”	Encorafenib + binimetinib with unresectable or metastatic melanoma with BRAF V600 mutations (>12 y)	LGG with BRAF fusion: R/R Newly diagnosed with unresectable/sub-totally resected
Waiver	NF1: 0–1 y; Thyroid cancer: 0–12 y; Melanoma: 12–18 y	0-1 y	Melanoma: 0–12 y; Solid tumours: 0–1 y	Melanoma: 0–12 y; Solid tumours: 0–1 month	0–6 months	0–18 years	0-12 y	0–6 months
Deferral	By September 2022	By December 2021	By June 2022	By June 2022	By July 2020	N/A	By June 2023	By July 2030
Formulation	Age-appropriate oral dosage form Capsule, hard	Capsule, hard Dispersible tablet	Capsule, hard Dispersible tablet	Film-coated tablet Powder for oral solution	Film-coated tablet Age-appropriate oral formulation	Film-coated tablet	Capsule, hard Age-appropriate oral dosage form	Tablet Age-appropriate paediatric formulation
Clinical	NF1 - inoperable plexiform	Advanced BRAF V600-mutant glioma:	Melanoma & Solid tumours:	Melanoma & Solid tumours:	R/R solid tumours with Ras, Raf or MEK	N/A	Unresectable or metastatic BRAF V600 mutant	Low-grade gliomas and

(continued on next page)

Table 4 (continued)

Product	Selumetinib (AZ/ Merck)	Dabrafenib + Trametinib (Novartis)	Dabrafenib mesylate (Novartis)	Trametinib dimethyl sulfoxide (Novartis)	Cobimetinib (Roche)	Vemurafenib (Roche)	Encorafenib + Binimetinib (Pierre Fabre)	DAY101 (DayOne)
	<p>neurofibromas:</p> <ul style="list-style-type: none"> • Single-arm → safety, toxicity, PK and activity (3–18 y) • Non-controlled, multiple-dose → PK, PD, safety, acceptability and activity (2–18 y). • Placebo-controlled, double-blind, randomised-withdrawal → PK, safety, tolerability and activity (1–7 y) • Thyroid Cancer: N/A 	<p>Open-label - safety and efficacy of dabrafenib + trametinib (1–18 y)</p>	<ul style="list-style-type: none"> • Single agent - safety, tolerability, PK and MTD (1–18 y) in advanced BRAF V600-mutant solid tumours. • Randomised, single dose 3-way cross-over relative bioavailability study in normal adult healthy volunteers. <p>Melanoma (BRAF V600-mutant): Measure (modelling and simulation) to demonstrate that PK, PD, and efficacy in adolescents (12–18 y) are similar to that in adults</p>	<ul style="list-style-type: none"> • Open-label, single agent, dose escalation trial → safety, tolerability, PK, PD in R/R solid malignant tumours (1 mo-18 y) • Relative bioavailability study in adults. 	<p>pathway activation: Multiple dose 2-stage trial to evaluate PK, safety and activity of cobimetinib (6 months-18 y) (GO29665/ NCT02639546)</p>		<p>melanoma: Multicentre, open-label → PK, safety, tolerability, and preliminary evidence of activity of binimetinib + encorafenib (12–18 y)</p>	<p>other RAS/RAF/ MEK/ERK pathway-activated tumours: dose finding study Relapsed or progressive low-grade gliomas harbouring BRAF fusions: open0label, single-arm trial → PK, safety, and activity of DAY101 (6m-18y) Newly diagnoses unresectable or sub-totally resected low-grade glioma harbouring BRAF fusions: randomised trial → safety and efficacy of DAY101 (6m-18y)</p>

With the increasing alignment between regulators in Europe and the US, there should be simultaneous regulatory submissions of individual PIPs and iPSPs to the EMA and FDA, respectively, including a suggestion for discussion at cluster calls [93–96]. Clinical trials should be designed to generate data supporting scientific, regulatory and payers (e.g. health technology assessment bodies in Europe) decision making, leading to regulatory approval with access for all children to the medicinal products.

5.2.1. Toxicity

In general, MEK inhibitors have been well tolerated with most toxicities being grade 1 and 2 with rare grade 3 and higher toxicities [22,97–99]. Currently, there has not been detailed comparison of the toxicity of differing MEK inhibitors, similarly data on long-term toxicity are lacking. Likewise, with BRAF inhibitors, grade 3 adverse effects are also rare and tend to be maculopapular rash, arthralgia and absence of pigment in the hair with the most frequent adverse effects being fatigue^{13,14,15}. In a randomised trial in pLGG of dabrafenib and trametinib compared to carboplatin and vincristine, there were less grade ≥ 3 adverse events with dabrafenib and trametinib [16]. In the future, quality of life of patients and patient-reported outcome assessment of the MAPK pathway inhibitors need to be assessed and clearly reported. Patient-reported outcomes have been used in the paediatric oncology application to the FDAs for selumetinib [100]. Furthermore, e-patient-reported outcomes hopefully can provide more accurate reporting of adverse events and the better evaluation of impact of those that are symptomatic [101].

5.3. Long-term follow-up

Long-term follow-up of patients receiving any new medicinal product is important so that survivors and their families, clinicians and regulatory agencies are informed of the long-term effects of treatment, including the potential for secondary malignancies. As the optimal duration of therapy is currently unknown and because the pathway is involved in normal development processes (especially glial differentiation), long-term follow-up assumes an even greater importance. It is crucial to know late effects which occur after five years or even longer as well as more short-term events. The ACCELERATE long-term follow-up initiative proposes an international and inter-company, harmonised and sustainable data registry of early and late adverse effects of new anti-cancer products, including MAPK pathway inhibitors [102]. This will provide informative data of the long-term safety to support the best use of these therapies, inform families and clinicians of the long-term effects of treatment in order to guide their decision making and support fulfilling

regulatory requirements of the marketing authorisation holders.

5.4. Paediatric formulation

In view of the age of patients who may potentially benefit from MAPK pathway inhibitors and for whom prolonged administration is required, the development of oral ‘child-friendly’ formulations (especially palatable suspensions or liquid formulations) of the medicinal product that are appropriate to be administered to young children is critical.

6. Specific themes

6.1. Better use of existing MAPK pathway inhibitors

Generally, monotherapy with a MAPK pathway inhibitor will result in a clinically relevant response rate in tumours with only one molecular driver [103]. However, for LCH and leukaemias, a molecular remission will likely not be obtained and when the MAPK inhibitor is discontinued, disease can recur as with pLGG and LCH. Therefore, there is a need for ‘deeper’ molecular, as well as clinical, responses. Multi-drug approaches are also required, which may be via combination with another MAPK inhibitor or, targeted agent, with chemotherapy. In other situations, where there are multiple mutations (e.g. pHGG with *BRAFV600E* and other mutations), MAPK inhibitors result in a 60–70% short duration response, after which resistance occurs. Studies are being carried out of combinations with BRAF and MEK inhibitors, and the results of these are awaited. In the absence of adult data, the design of such trials would be optimised if there were a randomised comparison between monotherapy and combination therapy rather than a retrospective comparison of response rates (e.g. the ROAR trial of dabrafenib plus trametinib in adult patients with *BRAFV600E*-mutant low-grade and high-grade glioma; NCT0203411 [104]). To accelerate drug development cross-company, cross-product combined analyses of toxicity would be invaluable.

Generally, MAPK inhibitors with higher CNS penetration are preferred for diseases affecting the brain, e.g. CNS tumours or metastatic disease to the brain from other cancers, and this is an important attribute of any inhibitor. Better brain penetration should reduce peripheral toxicity, as less systematic exposure is required to deliver sufficient drug to the brain/target tissue. The theoretical concern that higher CNS penetrance will lead to a greater incidence of CNS adverse events must be monitored. The width of the therapeutic window will depend on the magnitude of oncogene addiction of the tumour cells to aberrant MAPK signalling versus normal cells. However, MAPK inhibitors which have a higher CNS penetrance need to be studied

to determine if they are more effective than agents currently being used. As it is not possible to define the optimal biological dose in CNS tumours due to the inability to biopsy tumour tissue for pharmacodynamic assessment, dose escalation strategies should ideally target the pharmacokinetically defined exposure obtained in adults or, if that is not feasible, the maximum tolerated dose. Furthermore, it is conceivable that therapeutic plasma levels may vary according to tumour types, particularly between extra- and intra-cranial tumours. Pharmacodynamic and pharmacokinetic studies should be undertaken with the objective of relating these parameters to both efficacy and toxicity.

The optimal duration of therapy is currently unknown, may differ in different disease types and clinical evidence demonstrates that some patients relapse whilst others do not after discontinuation of therapy. It is proposed that patients are treated for an empirical duration from the best response or start of treatment and then treatment is discontinued. Ancillary biological studies must be integrated into trials to understand the heterogeneity in biology, monitor development of mutations and to inform rational duration of treatment and potential for development of resistance. Alternative approaches could be intermittent dosing or integrating other therapeutic modalities.

6.2. Best endpoints for MAPK pathway inhibitor trials for different diseases

In the tumour entities where MAPK inhibitors are being currently evaluated, there is a need to include additional end-points to overall survival and PFS. The number of patients in whom the cancer recurs after the discontinuation of therapy and the patterns of recurrence should also be captured. With CNS tumours, especially pLGG, visual function, quality of life, patient reported outcomes, motor function and neuropsychological functioning are invaluable and important end-points in the evaluation of innovative therapies. For these end-points to be considered by regulators, early discussions with regulatory agencies are required, involving academia, industry and patient advocates. A further challenge is defining appropriate end-points in LCH, particularly LCH-neurodegenerative syndrome.

6.2.1. Identifying the optimal MAPK inhibitors and combinations

There are a range of inhibitors of the MAPK pathway, including: type 1 RAF^{V600}, type 2 pan-RAF, MEK1, MEK1/2, ERK1/2, SOS1, KRAS^{G12C0} and pan-KRAS. Clinical trials need to be designed very carefully to ensure robust data are obtained regarding the optimal agents to take forward. For example, the benefits and role of ERK1/2 inhibitors require clarification. New generation BRAF inhibitors are very promising but clinical data are very early and in small numbers of

patients. The theoretical benefits of type 2 pan-RAF inhibitors compared to type 1 monomeric inhibitors have been postulated and demonstrated non-clinically, but they have not yet been confirmed in clinical trials. Peer-reviewed articles are eagerly awaited describing efficacy and toxicity.

6.3. Coordination of evaluation of products in development

With an increasing number of MAPK pathway inhibitors under or entering clinical evaluation with the intention of regulatory submissions, but a relatively small potential paediatric population with RAS/MAPK pathway-mutant diseases, international coordination is required to develop a strategy to identify the most effective drugs for children. The general proposed regulatory strategy, where there are multiple products of the same class, is that there is a consolidated agreement by industry and academia regarding which product or products, based on current evidence, is considered to have the highest potential to address unmet medical needs and minimises toxicity. This product(s) should then be advanced into paediatric development and submitted for regulatory approval, usually as part of PIP or iPSP, without delay (i.e. without a deferral). Part of this prioritisation discussion, however, also includes the need to decide on the sequence based on scientific arguments in which (any) other available (or emerging) products should be developed in reference to the one decided to move forward into development. The development of these products should be foreseen in sequence and in dependency so that as soon as a development is completed (either due to futility or efficacy); others are already prepared for evaluation. Regulatory tools like deferrals are in place to facilitate this within PIPs. Such consolidated prioritisation strategies allow fulfilment of the respective regulatory requirements, improves efficiency and is of benefit to children with malignancy. In the case of MAPK inhibitors, the development of some products is too advanced to employ this strategy now.

6.4. Patient access to MAPK inhibitors

MAPK inhibitors have the potential to make a substantial difference in several childhood malignancies and fulfil current unmet needs. Patients need access to new drugs which require both regulatory and payer (health technology assessment bodies) approval. One very important issue is that these new drugs are more costly than conventional therapy. The cost effectiveness of these innovative approaches needs to be robustly demonstrated to payers (e.g. health technology assessment bodies). Frequently, robust data about the effectiveness of established/standard therapies are not available for regulatory and health technology

assessment bodies purposes, creating a need to generate robust real-world evidence in this domain.

6.5. Evaluation of MAPK inhibitors in pLGG

MAPK inhibitors have the potential to fulfil unmet needs in pLGG and their development should be accelerated. The results of ongoing trials of single agents, and especially combinations in newly diagnosed patients are awaited and these will inform the field. Going forward, international coordination of trials in pLGG will be crucial to ensure progress is made rapidly and repetition is minimised. Defining the benefit of MAPK inhibitors compared to current standard of care, including economic evaluation, will establish how MAPK inhibitors could be practice changing treatments. Evaluating MAPK inhibitors with the greatest CNS penetration is of critical importance, although other characteristics of agents may also be important in defining the therapeutic window for MAPK inhibitors for LGG. Investigating the optimal MAPK inhibitors in a platform trial could be advantageous in identifying which to take forward to future front-line trials. Understanding biology in greater depth, including the role of promoting senescence versus blocking proliferation in the treatment of pLGG tumours, will allow predictive biomarkers to be identified to dissect the heterogeneous nature of the tumours, enabling therapy to be tailored. Similarly, biological studies will increase the understanding of rebound, resistance, optimal duration of therapy and late toxic effects. Validating new endpoints (e.g. visual acuity, quality-of-life, motor function, neuro-psychological function) and agreeing upon them prospectively with regulators for clinical trials are additional important goals.

6.6. Evaluation of MAPK inhibitors in pHGG with BRAF V600E mutations

Combination approaches are required, utilising inhibitors with the highest CNS penetration when feasible and safe. MAPK inhibitors are being incorporated in front-line therapy of pHGG with BRAF V600E mutations, with radiation therapy [67] and the results are awaited.

6.7. Evaluation of MAPK inhibitors in LCH

A high priority is to carry out intercontinental prospective trials evaluating the role of MAPK inhibitors in relapsed high-risk LCH (e.g. inclusion in a modified stratum III of the LCH IV trial: second-line therapy for high-risk). The substantial toxicity of current chemotherapeutic approaches further highlights the need for these approaches. Knowledge of the efficacy of MAPK inhibitors is not being systematically gained with the current substantial off-label use. There is a clear unmet

need for companies to work in partnership with established histiocyte-focused cooperative groups to generate scientific knowledge that could be used for regulatory purposes. The second high priority in LCH is a trial that systematically investigates the value of MAPK inhibitors in LCH-neurodegenerative, especially since this devastating condition is not curable with the currently available chemotherapy and/or immunomodulation.

6.8. Evaluation of MAPK in RASopathies and other solid tumours

MAPK inhibitors will highly likely have a major role in other RASopathies caused by germline pathogenic variants in genes that encode RAS pathway proteins in addition to NF1, including malignant peripheral nerve sheath tumours, Noonan syndrome, cardiofaciocutaneous syndrome and Costello syndrome [105]. The role of MAPK inhibitors in other solid tumours (neuroblastoma and rhabdomyosarcoma [42,43]) is more complicated, in view of the complex genomic landscape and long pipeline of agents already under investigation. This is exemplified in the paediatric MATCH phase 2 trial Arm E which evaluated selumetinib in tumours harbouring activating MAPK pathway genetic alterations, but excluded LGG. Selumetinib demonstrated limited efficacy, indicating that pathway mutation status alone is insufficient to predict response to selumetinib [103].

7. Conclusions

In view of the MAPK signalling cascade being frequently activated across paediatric cancers, the development of successful therapeutic approaches to inhibit the pathway and monitoring validated functional endpoints in treated children with MAPK-pathway driven diseases are critical goals. Understanding specific tumour biology is crucial to develop the optimal combinations, to avoid paradoxical growth and to prevent unintended consequences including severe acute and late toxicity. The development of MAPK pathway inhibitors to date has been predominantly driven by adult indications. However, these inhibitors can address unmet paediatric needs in pLGG, pHGG, LCH, plexiform neurofibroma, JMML and potentially other paediatric tumours [Box 1](#).

The rapid development and evaluation of combination approaches (ideally combining agents which each show single agent activity and non-overlapping toxicity is required to optimise responses and to achieve more profound molecular and clinical responses. Furthermore, determining the optimal duration of therapy is important; treatment for an empirical, but well defined duration with integrated ancillary biological studies should facilitate establishing the rational duration of

Box 1. Text box of key conclusions of the Paediatric Strategy Forum

- The mitogen-activated protein kinase (MAPK) signalling pathway is activated in many paediatric cancers
- It is an important therapeutic target
- MAPK also signals through many other cascades and their feedback loops, and perturbing the MAPK pathway may have substantial influence on other pathways
- Development of MAPK pathway inhibitors to date has been predominantly driven by adult indications (e.g. malignant melanoma)
- MAPK inhibitors can address many unmet needs in paediatric low-grade gliomas, paediatric high-grade gliomas, Langerhans cell histiocytosis, plexiform neurofibroma and juvenile myelomonocytic leukaemia
- Although MAPK inhibitors have demonstrated activity, breadth and depth of responses need to be improved
- Better inhibitors with higher central nervous system penetration for cancers located in the brain need to be studied to determine if they are more effective than agents currently being used
- Rapid development and evaluation of combination approaches is required to optimise responses
- Understanding specific tumour biology is crucial to develop the optimal combinations, to avoid paradoxical growth and to prevent unintended consequences including severe toxicity
- Optimum duration of therapy with MAPK inhibition needs to be determined, by rationally designed studies
- Systematic and coordinated development of treatment strategies with MAPK inhibitors, rather than off-label use is needed to assess the risks and benefits of these agents and combination strategies in front-line and salvage settings.
- Platform trials could have an important role
- There is a major need for the international coordination of evaluation of products in development, in view of their number and a relatively small potential paediatric population, with RAS/MAPK pathway-driven diseases
- Accelerating the introduction of MAPK inhibitors into front-line studies is a priority, as is ensuring that these studies generate data appropriate for regulatory purposes
- Early discussions with regulators are crucial, in designing trials
- Additional functional end-points e.g. visual acuity, quality-of-life, motor function and neuro-psychological function are important so that these agents benefit children with paediatric low-grade gliomas and should be included in initial designs and agreed upon prospectively with regulators
- Long-term follow-up of patients receiving these inhibitors is crucial in view of their prolonged administration and the involvement of the pathway in normal development

treatment. Accelerating the introduction of MAPK inhibitors into front-line studies is a priority, as is ensuring that these studies generate data appropriate for regulatory purposes. Early discussion with regulators is crucial, particularly if randomised control trials are challenging to perform.

Additional end-points of function and quality of life (as these outcomes are often more reflective of benefit for lower grade tumours such as paediatric low-grade glioma and plexiform neurofibroma) should be included in initial study designs for pLGG and agreed upon prospectively with regulators.

8. Participants

Brian Abbott
 Isabelle Aerts
 Sama Ahsan
 Russo Alexandra
 Carl Allen
 Lise Alter
 Evangelia Antoniou
 John Apps
 Sebastian Asaftei
 Shifra Ash
 Itziar Astigarraga
 Pratiti (Mimi) Bandopadhyay

Amy Barone
 Elly Barry
 Immanuel Barth
 Sylvie Benchetrit
 Carly Bergstein
 Hana Bernatikova
 Michael Berntgen

BioMed Valley Discoveries, Kansas City, Missouri, USA
 Institute Curie, France
 Merck & Co., Inc., Rahway, NJ, USA
 University Medicine, Mainz
 Texas Children Hospital, Houston, Texas, USA
 Haute Autorité de Santé, Saint-Denis, France
 Paediatric Clinic III, University Hospital of Essen, Germany
 University of Birmingham, UK
 Città della salute e della scienza Turin, Paediatric Onco-Haematology, Turin, Italy
 Rambam Health Care Campus, Haifa, Israel
 Hospital Universitario Cruces, Barakaldo, Spain
 Harvard Medical School, Dana-Farber, Boston Children's Cancer and Blood Disorders Centre, Boston, USA
 US Food and Drug Administration, USA
 Day One Biopharmaceuticals, USA
 Paediatric Committee of the European Medicines Agency, Netherlands
 Agence Nationale de Sécurité du Médicament et des Produits (ANSM), France
 The Andrew McDonough B + Foundation, USA
 University Hospital Brno, Department of Paediatric Oncology, Czech Republic
 European Medicines Agency, Netherlands

(continued)

Nicholas Bird	Solving Kids' Cancer, UK
Samuel Blackman	Day One Biopharmaceuticals, USA
Patricia Blanc	Imagine for Margo, France
Eric Bouffet	The Hospital for Sick Children, Toronto, Canada
Liora Brunel	Agence Nationale de Sécurité du Médicament et des Produits (ANSM), France
Vickie Buenger	Coalition Against Childhood Cancer (CAC2), USA
Gilbert Burckart	US Food and Drug Administration, USA
Quentin Campbell Hewson	Great North Children's Hospital, Newcastle Upon Tyne, UK
Giordano Caponigro	Novartis, USA
Jorge Caravia	Day One Biopharmaceuticals, USA
Hubert Caron	F. Hoffmann-La Roche, Switzerland
Michela Casavova	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Monica Cellini	Azienda Ospedaliero-Universitaria di Modena, Italy
Carla Centeno	McGill Institute, Montreal, Canada
Antony Ceraulo	Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe), Lyon, France.
Jordane Chaix	Institut Gustave Roussy, Paris, France
Guillermo Chantada	International Society of Paediatric Oncology
Katharine Cheng	Conect4children (c4c)
Alexander Chesi	Novartis, USA
Eric Chetaille	Pierre-Fabre, Paris, France
Davy Chiodin	Day One Biopharmaceuticals, USA
Devalck Christine	European Paediatric Soft tissue sarcoma Study Group (EpSSG)
Céline Chu	Agence Nationale de Sécurité du Médicament et des Produits (ANSM), France
Pierre Cochat	Haute Autorité de Santé, Saint-Denis, France
Nadège Corradini	Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe), Lyon, France.
Marta Cortes	Hospital Materno Infantil Malaga, Spain
Mireille Costantzer	F. Hoffmann-La Roche, Switzerland
Michael Cox	Day One Biopharmaceuticals, USA
Monika Csóka	Semmelweis University, 2nd Department of Pediatrics, Budapest
Randolph de la Rosa Rodriguez	AstraZeneca
Teresa de Rojas	ACCELERATE
Boris Decarolis	University Hospital of Cologne, Germany
Andrea Demadonna	ACCELERATE
Monique den Boer	Princess Máxima Centre, Utrecht, the Netherlands
Clare Devlin	F. Hoffmann-La Roche, Switzerland
Rebecca Deyell	BC Children's Hospital, Vancouver, Canada
Daniela Di Carlo	Gustave Roussy Cancer Centre, Paris, France
Maria do Céu Diniz Borborema	Instituto de Medicina Integral Professor Fernando Figueira (IMIP), Pernambuco, Brazil
Michael Dolton	F. Hoffmann-La Roche, Switzerland
Martha Donoghue	US Food and Drug Administration, USA
Aizpea Echebarria	Hospital Universitario Cruces
Carrie Emery	BioMed Valley Discoveries, USA
Natacha Entz-Werle	University Hospital of Strasbourg, Strasbourg, France
Craig Erker	IWK Health Centre, Halifax, Canada
Samira Essiaf	ACCELERATE
Jason Fangusaro	Children's Healthcare of Atlanta and Emory, Atlanta, USA
Roula Farah	Lau Medical Centre Rizk Hospital, Beirut, Lebanon
Ana Fernandez-Teijeiro	Spanish Society of Paediatric Haematology and Oncology
Michael Fisher	Children's Hospital of Philadelphia, Philadelphia, USA
Christian Flotho	Division of Paediatric Haematology and Oncology, University Medical Centre, Freiburg, Germany
Deanna Fournier	Histiocytosis Association, USA
Elizabeth Fox	St Jude Children's Research Hospital, Tennessee, USA
Barry Frankel	BioMed Valley Discoveries, USA
Marion Gambart	CHU Toulouse, Toulouse, France
Julia Glade Bender	Memorial Sloan Kettering Cancer Centre, New York, USA
Lia Gore	Children's Hospital Colorado/University of Colorado, Colorado, USA
Marcus Guardian	European Network for Health Technology Assessment (EUNETHTA)
Daphne Haas-Kogan	Dana-Farber/Brigham and Women's Cancer Centre, Boston, USA
Todd Hankinson	Children's Hospital Colorado/University of Colorado, Colorado, USA
Jordan Hansford	Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) Brain Group
Darren Hargrave	UCL Great Ormond Street Institute of Child Health, London, UK
Doug Hawkins	Seattle Children's Hospital, Seattle USA
Niklas Hedberg	Dental and Pharmaceutical Benefits Agency, TLV, Sweden

(continued on next page)

(continued)

Lars Hjorth	Skane University Hospital, Malmö, Sweden
Laura Huggins	Novartis, USA
Caroline Hutter	St. Anna Children's Hospital, Children's Cancer Research Institute, Vienna, Austria
Uri Ilan	Princess Máxima Centre, Utrecht, the Netherlands
Vesna Ilic	Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Uche Iloeje	SpringWorks Therapeutics, USA
Sae Ishimaru	Princess Máxima Centre, Utrecht, the Netherlands
Shai izraeli	Schneider Children's Medical Centre, Petah Tikva, Israel Matej Jelic University Hospital Centre Zagreb
David Jones	German Cancer Research Centre (DKFZ)
Dominik Karres	European Medicines Agency
Rejin Kebudi	Istanbul University Oncology Institute, Istanbul, Turkey
Sophie Kelley	Haute Autorité de Santé, Saint-Denis, France
Olga Kholmanskikh	Federal Agency for Medicines and Health Products, Belgium
Mark Kieran	Day One Biopharmaceuticals, USA
Maria Kirby	Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG)
George Kirk	AstraZeneca, UK
Deb Knoerzer	BioMed Valley Discoveries, USA
Leona Knox	Solving Kids Cancer, UK
Uwe Kordes	Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany
Ewa Koscielniak	Klinikum Stuttgart, Stuttgart, Germany
Menia Koukougiani	NGgo Karkinaki Awareness for Childhood and Adolescent Cancer
Brent Kreider	BioMed Valley Discoveries, USA
Karin Langenberg	Princess Máxima Centre, Utrecht, the Netherlands
Abe Langseth	SpringWorks Therapeutics, USA
Alvaro Lasseletta	Hospital Infantil Universitario Nino Jesus, Madrid, Spain
Giovanni Lesa	European Medicines Agency
Haveman Lianne	Princess Máxima Centre, Utrecht, the Netherlands
Franca Ligas	European Medicines Agency
Andrej Lissat	Charité – Universitätsmedizin, Berlin, Germany
Donna Ludwinski	Solving Kids' Cancer, USA
Lusong Luo	SpringWorks Therapeutics, USA
Margaret Macy	Children's Hospital Colorado/University of Colorado, Colorado, USA
Helen Mao	Health Canada
Marcelo Marotti	Boehringer Ingelheim, Germany
Lynley Marshall	Royal Marsden Hospital and The Institute of Cancer Research, UK
Rene Mathiasen	Righospitalet, Copenhagen, Denmark
Joe McDonough	The Andrew McDonough B + Foundation, USA
Milen Minkov	St. Anna Children's Hospital, Children's Cancer Research Institute, Vienna, Austria
Jan Molenaar	Princess Máxima Centre, Utrecht, the Netherlands
Abby Mueller	SpringWorks Therapeutics, USA
Jean Mulcahy	Levy University of Colorado Anschutz, Aurora, Colorado
Miho Nakajima	National Cancer Centre Hospital
Kahina Nasri	Pierre-Fabre, Paris, France
Robert (Skip) Nelson	Multi-Regional Clinical Trial Centre (MRCT)
Charlotte Niemeyer	European Working Group of Myelodysplastic Syndrome and Severe Aplastic Anaemia in children and adolescents
Liana Nobre	The Hospital for Sick Children, Toronto, Canada
Koen Norga	Paediatric Committee of the European Medicines Agency, Righospitalet, Copenhagen, Denmark
Karsten Nysom	Righospitalet, Copenhagen, Denmark
Heidenreich Olaf	Princess Máxima Centre, Utrecht, the Netherlands
Enrico Opocher	Az Ospedaliera di Padova, Padua, Italy
Vassilios Papadakis	Agia Sofia Children's Hospital, Athens, Greece
Alberto Pappo	St Jude Children's Research Hospital, Tennessee, USA
Vanessa Passos	Novartis, USA
Zdenek Pavelka	University Hospital Brno, Dept. of Paediatric Oncology, Brno Czech Republic
Andy Pearson	ACCELERATE
Apostolos Pourtsidis	Children's Hospital Mitera, Athens, Greece
Lueder H. Meyer	Ulm University Medical Centre, Dpt. Pediatrics and Adolescent Medicine, Ulm, Germany
Nathalie Thomas Pujol	Pierre-Fabre, Paris, France
Eduardo Quiroga	Hospital Infantil Virgen del Rocio, Seville, Spain
Sandya Raju	Day One Biopharmaceuticals, USA
Jitesh Rana	SpringWorks Therapeutics, USA
Gregory Reaman	US Food and Drug Administration
Marleen Renard	Paediatric Committee of the European Medicines Agency, Netherlands
Gianluca Rossato	F. Hoffmann-La Roche, Switzerland

(continued)

Alba Rubio	San Simón Niño Jesús Hospital Madrid, Spain
Mark Russo	Novartis, USA
Magnus Sabel	Queen Silvia Children's Hospital, Gothenburg, Sweden
Raoul Santiago	CHU de Québec - Université Laval, Quebec City, Canada
Katrin Scheinemann	Kantonsspital Aarau, Aarau, Switzerland
Anja Schiel	Norwegian Medicines Agency
Nicole Scobie	Zoé4life, Switzerland and Childhood Cancer International- Europe
Astrid Sehested	Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Nita Seibel	CTEP-National Cancer Institute, Maryland, USA
Wenlin Shao	SpringWorks Therapeutics, USA
Patricia Shay	SpringWorks Therapeutics, USA
Peter Sisovsky	State Institute for Drug Control in Slovakia and European Medicines Agency
Malcolm Smith	National Cancer Institute, Maryland, USA
Karen So	AstraZeneca, UK
Kerstin Sollerbrant	The Swedish Childhood Cancer Fund
Jaroslav Sterba	University Hospital Brno, Brno, Czechia
Elliot Stieglitz	University of California San Francisco Parnassus Campus, San Francisco, California
Reghu Sukumaran	Tata Medical Centre, Kolkata, West Bengal, India
Uri Tabori	The Hospital for Sick Children, Toronto, Canada
Kazuki Tanimura	National Cancer Centre Hospital
Sarah Tasian	Children's Hospital of Philadelphia, Philadelphia, USA
Anne Thorwarth	Charité Universitymedicine, Berlin, Germany
Helen Toledano	Schneider Children's Medical Centre, Petah Tikva, Israel
Silvia Torrejon Almeida	Hospital Regional Universitario de Málaga, Málaga, Spain
Aina Ulvmoen	Oslo University Hospital, Oslo, Norway
Renu Vaish	SpringWorks Therapeutics, USA
Lorena Valero	Vall d'Hebron Hospital, Barcelona, Spain
Paula Valle	Simón Hospital Universitario La Paz, La Paz, Bolivia,
Maaïke van Dartel	Paediatric Committee of the European Medicines Agency, Netherlands
Cornelis van Tilburg	Hopp Children's Cancer Centre (KiTZ), Heidelberg University Hospital and German Cancer Research Centre, Heidelberg, Germany
Magimairajan Issai	Vancouver Cancer Care Manitoba, Canada
Gilles Vassal	ACCELERATE
Jean Claude Vedovato	Pierre-Fabre, Paris, France.
Eleni Venetsanakos	Day One Biopharmaceuticals, USA
Ruth Viana Alvarez	Alexion, Alexion Pharmaceuticals, Zurich, Switzerland
Arend von Stackelberg	Charité Universitätsmedizin, Berlin, Germany
Siri Wang	Paediatric Committee of the European Medicines Agency, Netherlands
Katherine Warren	Dana-Farber, Cancer Centre, Boston, USA
Yuko Watanabe	National Cancer Centre Hospital
Brenda Weigel	University of Minnesota, Minneapolis, Minnesota
Susan Weiner	Children's Cancer Cause, Washington DC, USA
Amy Weinstein	Paediatric Brain Tumor Foundation, Atlanta, USA
James Whitlock	Hospital for Sick Children & C17 Council, Toronto, Canada
Aleksandra Wiczorek	Jagiellonian University Medical College, Department of Paediatric Oncology and Hematology, Kraków, Poland
Beate Wieseler	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, (IQWiG)
Leen Willems	University Hospital Ghent, Ghent, Belgium
Olaf Witt	Hopp Children's Cancer Centre (KiTZ), Heidelberg University Hospital and German Cancer Research Centre, Heidelberg, Germany
Beate Wulff	F. Hoffmann-La Roche, Switzerland
Jessica Yecies	Day One Biopharmaceuticals, USA
Isabelle Yoldjian	Agence Nationale de Sécurité du Médicament et des Produits (ANSM), France
Oezlem Yuce-Petronczki	Boehringer Ingelheim, Germany
Michal Zapotocky	University Hospital Motol in Prague, Prague, Czech Republic
Yuan Zhu	Children's National Hospital
Michel Zwaan	Princess Máxima Centre, Utrecht, the Netherlands & Erasmus MC, Rotterdam, the Netherlands

Long-term follow-up of patients receiving MAPK pathway inhibitors is particularly crucial in view of the prolonged administration that is currently required and the involvement of the MAPK pathway in normal development. Currently, late sequelae of therapy

are unknown and determining these are critically important especially in good prognosis tumours. The ACCELERATE long-term follow-up initiative should provide an appropriate infrastructure to accomplish this important task.

Role of funding source

Andrew McDonough B + Foundation for financial support of ACCELERATE.

Disclaimer

The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of, or reflecting the position of, the agencies or organisations with which the authors are affiliated. As well, this publication reflects the views of the author and should not be construed to represent Food and Drug Administration views or policies.

Conflict of interest statement

SA is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stockholder of Merck & Co., Inc., Rahway, NJ, USA. EB is an employee of Day One Biopharmaceuticals PB receives grant funding from Novartis Institute of Biomedical Research and has received grant funding from Deerfield Therapeutics and has been a member of an advisory board for QED Therapeutics. JF has served as an advisor for Astra-Zeneca and has been a member of a Paediatric Advisory Board. BK is an employee of BioMed Valley Discoveries. AJL is an employee and stockholder of SpringWorks Therapeutics. MM is an employee of Boehringer Ingelheim. KNa is an employee of Pierre-Fabre. GR is an employee of Hoffmann-La Roche AG. MR is an employee and stockholder of Novartis. RV is an employee of Alexion Pharmaceuticals ADJP has consulted for Lilly, Norgine and Developmental Therapeutics Consortium Limited and been an advisor for Amgen. All remaining authors have declared no conflicts of interest.

Acknowledgements

The authors very gratefully acknowledge Andrea Demadonna for his dedication, efficiency, enthusiasm and very substantial work in preparation of the Forum and Samira Essiaf for her pivotal role in organising the Forum. The authors thank Eric Smith for his assistance in generating the Figure, Gynette Cook for preparation of the manuscript and Sarah K. Tasian for her critical review of the summary.

References

- [1] Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. *Cancers* 2019;11:1618. <https://doi.org/10.3390/cancers1110161>.
- [2] Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. *Nature* 2018;555:321–7.
- [3] Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. *Nature* 2018; 555:371–6.
- [4] Ney GM, McKay L, Koschmann C, Mody R, LiQ. The emerging role of Ras pathway signaling in pediatric cancer. *Cancer Res* 2020;80:5155–63.
- [5] Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. *Cell* 2017;170:17–33.
- [6] Poulidakos PI, Sullivan RJ, Yaeger R. Molecular pathways and mechanisms of BRAF in cancer therapy. *Clin Cancer Res* 2022; clincanres. 2138:2021. <https://doi.org/10.1158/1078-0432.CCR-21-2138>.
- [7] Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS G12C inhibition with Sotorasib in advanced solid tumors. *N Engl J Med* 2020;383:1207–17.
- [8] The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. *ESMO Open* 2021;6:100031. <https://doi.org/10.1016/j.esmoop.2020.100031>.
- [9] Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss BI, Kim A, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. *N Engl J Med* 2016;375:2550–60.
- [10] Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. *N Engl J Med* 2020;382:1430–42.
- [11] Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas (Erratum). *N Engl J Med* 2020;383:1290.
- [12] Casey D, Demko S, Sinha A, Mishra-Kalyani PS, Shen YL, Khasar S, et al. FDA approval summary: selumetinib for plexiform neurofibroma. *Clin Cancer Res* 2021;27:4142–6.
- [13] Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, et al. Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I/IIa study. *Clin Cancer Res* 2019;25:7303–731.
- [14] Kieran MW, Georger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P, et al. A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors. *Clin Cancer Res* 2019;25:7294–302.
- [15] Wright K, Krzykwa E, Greenspan L, Chi S, Yeo KK, Prados M, Mueller S, et al. CTNI-19. Phase I trial of Day101 in pediatric patients with radiographically recurrent or progressive low grade glioma (LGG). *Neuro Oncol* 2020;22(Supplement 2):ii46.
- [16] Bouffet E, Hansford J, Garre ML, Hara J, Plant-Fox A, Aerts I, et al. Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600-mutant pediatric low-grade glioma (pLGG). *J Clin Oncol* 2022;36(suppl). abstr LBA2022.
- [17] Hargrave DR, Moreno L, Broniscer A, Bouffet E, Aerts I, Andre N, et al. Dabrafenib in pediatric patients with BRAF V600-positive high-grade glioma (HGG). *J Clin Oncol* 2018; 36(suppl). abstr 10505.
- [18] Andrews LJ, Thornton ZA, Saincher SS, Yao IY, Dawson S, McGuinness LA, et al. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. *Neuro Oncol* 2022;24: 528–40.
- [19] Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, et al. Vemurafenib for refractory multisystem Langerhans cell

- histiocytosis in children: an international observational study. *J Clin Oncol* 2019;37:2857–65.
- [20] Juratli TA, Jones PS, Wang N, Subramanian M, Aylwin SJB, Oda Y, et al. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. *Cancer* 2019;125:2910–4.
- [21] Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multi-centre, phase 2 trial. *Lancet Oncol* 2019;20:1011–22.
- [22] Selt F, van Tilburg CM, Bison B, et al. Response to trametinib treatment in progressive pediatric low-grade glioma patients. *J Neuro Oncol* 2020;149:499–510.
- [23] Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. *Nature* 2019;567:521–4.
- [24] Stieglitz E, Loh ML, Meyer J, Zhang C, Barkauskas DA, Hall D, et al. MEK inhibition demonstrates activity in relapsed, refractory patients with juvenile myelomonocytic leukemia: results from COG study ADVL1521. *Blood* 2021;138(Supplement 1):3679.
- [25] Vassal G, Rousseau R, Blanc P, Moreno L, Bode G, Schwoch S, et al. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. *Eur J Cancer* 2015;51:218–24.
- [26] Pearson ADJ, Weiner SL, Adamson PC, Karres D, Reaman G, Rousseau R, et al. Accelerate - five years accelerating cancer drug development for children and adolescents. *Eur J Cancer* 2022;166:145–64.
- [27] Pearson ADJ, Scobie N, Norga K, Ligas F, Chiodin D, Burke A, et al. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. *Eur J Cancer* 2019;110:74–85.
- [28] Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, et al. ACCELERATE and European medicines agency paediatric strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. *Eur J Cancer* 2020;127:52–66.
- [29] Pearson ADJ, Kolb EA, Zwaan CM, Karres D, Guillot J, Kim SY, et al. Paediatric strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents. *Eur J Cancer* 2020;136:116–29.
- [30] Pearson AD, Stegmaier K, Bourdeaut F, Reaman G, Heenen D, Meyers ML, et al. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. *Eur J Cancer* 2020;139:135–48.
- [31] Pearson ADJ, Barry E, Mosse YP, Ligas F, Bird N, de Rojas T, et al. Second paediatric strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies ACCELERATE in collaboration with the European medicines agency with the participation of the Food and drug administration. *Eur J Cancer* 2021;157:198–213.
- [32] Pearson ADJ, Rossig C, Mackall C, Shah NN, Baruchel A, Reaman G, et al. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. *Eur J Cancer* 2022;160:112–33.
- [33] Pearson ADJ, Gaspar N, Janeway K, Campbell-Hewson Q, Lawlor ER, Copland C, et al. Paediatric strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. *Eur J Cancer* 2022;173:71–90.
- [34] Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang Y-D, Mazor T, et al. The genomic landscape of juvenile myelomonocytic leukemia. *Nat Genet* 2015;47:1326–33.
- [35] Bandopadhyay P, Ramkissoon LA, Jain P, Berghthold G, Wala J, Zeid R, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. *Nat Genet* 2016;48:273–82.
- [36] Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. *Nat Genet* 2013;45:602–12.
- [37] Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. *Cancer Res* 2008;68:8673–7.
- [38] Jones DTW, Bandopadhyay P, Jabado N. The Power of human cancer genetics as Revealed by low-grade gliomas. *Annu Rev Genet* 2019;53:483–503.
- [39] Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, et al. Integrated molecular Meta-analysis of 1,000 pediatric high-grade and Diffuse Intrinsic Pontine glioma. *Cancer Cell* 2017;32:520–37.
- [40] Izquierdo E, Carvalho DM, Mackay A, Temelso S, Boulton JKR, Pericoli G, et al. DIPG Harbors alterations targetable by MEK inhibitors, with Acquired resistance mechanisms Overcome by Combinatorial inhibition. *Cancer Discov* 2022;12:712–29.
- [41] Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. *Blood* 2014;124:3007–15.
- [42] Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. *Cancer Discov* 2014;4:216–31.
- [43] Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. *Nat Genet* 2015;47:864–71.
- [44] Rankin A, Johnson A, Roos A, Kannan G, Knipstein J, Britt N, et al. Targetable BRAF and RAF1 alterations in advanced pediatric cancers. *Oncol* 2021;26:e153–63. <https://doi.org/10.1002/ONCO.13519>.
- [45] Legius E, Messiaen L, Wolkenstein P, Panza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. *Genet Med* 2021;23:1506–13.
- [46] Gutmann DH, Parada LF, Silva AJ, Ratner N. Neurofibromatosis type 1: modeling CNS dysfunction. *J Neurosci* 2012;32:14087–93.
- [47] Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. *Lancet Neurol* 2014;13:834–43.
- [48] Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nat Genet* 2013;45:927–32.
- [49] Bigenwald C, Le Berichel J, Wilk CM, Chakraborty R, Chen ST, Tabachnikova A, et al. BRAF V600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. *Nat Med* 2021;27:851–61.
- [50] Clymer J, Bandopadhyay P. Old meet new-the path to combination treatments in pediatric low-grade gliomas. *Neuro Oncol* 2019;21:143–5.
- [51] Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. *Neuro Oncol* 2017;19:774–85.
- [52] Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, Harter DH, et al. Phase II study of sorafenib in

- children with recurrent or progressive low-grade astrocytomas. *Neuro Oncol* 2014;16:1408–16.
- [53] Krens SFG, Spaink HP, Snaar-Jagalska BE. Functions of the MAPK family in vertebrate-development. *FEBS Lett* 2006;580:4984–90.
- [54] Ihermann-Hella A, Lume M, Miinalainen IJ, Pirttiniemi A, Gui Y, Peränen J, et al. Mitogen-activated protein kinase (MAPK) pathway regulates branching by remodeling epithelial cell adhesion. *PLoS Genet* 2014;10:e1004193.
- [55] Li X, Newbern JM, Wu Y, Morgan-Smith M, Zhong J, Charron J, et al. MEK is a key regulator of gliogenesis in the developing brain. *Neuron* 2012;75:1035–50.
- [56] Scholl FA, Dumesic PA, Barragan DI, Harada K, Bissonauth V, Charron J, et al. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. *Dev Cell* 2007;12:615–29.
- [57] Greuter L, Guzman R, Soleman J. Pediatric and adult low-grade gliomas: where do the differences Lie? *Children* 2021;8:1075. <https://doi.org/10.3390/children8111075>.
- [58] Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤ 16 years) low grade glioma - a final report. *Eur J Cancer* 2017;81:206–25.
- [59] Kandels D, Pietsch T, Bison B, Warmuth-Metz M, Thomale UW, Kortmann RD, et al. Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients-Report from the German SIOP-LGG 2004 cohort. *Int J Cancer* 2020;147:3471–89.
- [60] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol* 2021;23:1231–51.
- [61] <https://www.who.int/docs/default-source/documents/health-topics/cancer/who-childhood-cancer-overview-booklet.pdf>. (Accessed 8 July 2022).
- [62] Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. *Neuro Oncol* 2021;23:1777–88.
- [63] Buhl JL, Selt F, Hielscher T, Guiho R, Ecker J, Sahm F, et al. The senescence-associated secretory phenotype Mediates oncogene-induced senescence in pediatric pilocytic astrocytoma. *Clin Cancer Res* 2019;25:1851–66.
- [64] Jacob K, Quang-Khuong DA, Jones DT, Witt H, Lambert S, Albrecht S, et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. *Clin Cancer Res* 2011;17:4650–60.
- [65] Reitman ZJ, Paoletta BR, Berghold G, Pelton K, Becker S, Jones R, et al. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. *Nat Commun* 2019;10:3731.
- [66] Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhyay P, Bornhorst M, et al. Pediatric low-grade gliomas: next biologically driven steps. *Neuro Oncol* 2018;20:160–73.
- [67] Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, Perry A, Lichter P, von Deimling A, Pfister SM, Jones DT. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. *Acta Neuropathol* 2015;129:669–78.
- [68] Phase II Pediatric Study with Dabrafenib in Combination with Trametinib in Patients with HGG and LGG - <https://clinicaltrials.gov/ct2/show/NCT02684058>. (Accessed 8 July 2022).
- [69] Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma. <https://clinicaltrials.gov/ct2/show/NCT03919071>. (Accessed 6 September 2022).
- [70] Study of Binimetinib with Encorafenib in Adults with Recurrent BRAF V600-Mutated HGG (BRAF). <https://clinicaltrials.gov/ct2/show/NCT03973918>. (Accessed 6 September 2022).
- [71] A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients with Recurrent LGG or HGG with a BRAF Aberration. <https://clinicaltrials.gov/ct2/show/NCT04201457>. (Accessed 6 September 2022).
- [72] Rosenberg T, Yeo KK, Mauguen A, Alexandrescu S, Prabhu SP, Tsai JW, et al. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. *Neuro Oncol* 2022. <https://doi.org/10.1093/neuonc/noac096>.
- [73] Schreck KC, Morin A, Zhao G, Allen AN, Flannery P, Glantz M, et al. Deconvoluting mechanisms of Acquired resistance to RAF inhibitors in BRAF V600E-mutant human glioma. *Clin Cancer Res* 2021;27:6197–208.
- [74] Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen SS. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic Literature review. *Adolesc Health Med Ther* 2021;12:55–66.
- [75] Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tongard JH, Blakeley J, et al. NF106: a neurofibromatosis clinical trials Consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. *J Clin Oncol* 2021;39:797–806.
- [76] Solares I, Viñal D, Morales-Conejo M, Rodriguez-Salas N, Feliu J. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. *ESMO Open* 2021;6:100223. <https://doi.org/10.1016/j.esmoop.2021.100223>. [Accessed 8 July 2022].
- [77] Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. *N Engl J Med* 2018;379:856–68.
- [78] Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, et al., Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. *Blood* 2013;121:5006–14.
- [79] Minkov M, Steiner M, Pötschger U, Aricò M, Braier J, Donadieu J, et al. International Study Group. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. *J Pediatr* 2008;153:700–5.
- [80] Yeh EA, Greenberg J, Abala O, Longoni G, Diamond E, Hermiston M, et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. *Pediatr Blood Cancer* 2018;65. <https://doi.org/10.1002/pcb.26784>.
- [81] Badalian-Very G, Vergilio J -A, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. *Blood* 2010;116:1919–23.
- [82] Eckstein OS, Visser J, Rodriguez-Galindo C, Allen CE. NACHO-LIBRE Study Group. Clinical responses and persistent BRAF V600E + blood cells in children with LCH treated with MAPK pathway inhibition. *Blood* 2019;133:1691–4.
- [83] Hyman DM, Diamond EL, Vibat CRT, Hassaine L, Poole JC, Patel M, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. *Cancer Discov* 2015;5:64–71.
- [84] Eder SK, Schwentner R, Soussia PB, Abagnale G, Attarbaschi A, Minkov M, et al. Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis. *Blood Adv* 2022;6:970–5.
- [85] Whitlock JA, Georger B, Roughton M, Choi J, Osterloh L, Russo M et al. Dabrafenib, alone or in combination with

- trametinib, in Pediatric patients with BRAF V600 mutation-positive Langerhans cell histiocytosis <https://ashpublications.org/blood/article/138/Supplement201/3618/479771/> (Accessed 6 September 2022).
- [86] Trametinib in Treating Patients with Relapsed or Refractory Juvenile Myelomonocytic Leukemia. <https://clinicaltrials.gov/ct2/show/NCT03190915>. (Accessed 6 September 2022).
- [87] Antić Ž, Yu J, Van Reijmersdal SV, Van Dijk A, Dekker L, Segerink WH, et al. Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of sub-clonal mutations. *Haematologica* 2021;106:3046–55.
- [88] Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. *Blood* 2014;124:3420–30.
- [89] International Trial of Selumetinib in Combination with Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex). <https://clinicaltrials.gov/ct2/show/NCT03705507>. (Accessed 6 September 2022).
- [90] Menne T, Slade D, Savage J, Johnson S, Irving J, Kearns P, Plummer R, et al. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial. *BMJ Open* 2022;12:e059872.
- [91] Hyrenius-Wittsten A, Pilheden M, Stureson H, Hansson J, Walsh MP, Song G, et al. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. *Nat Commun* 2018;9:1770.
- [92] <https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000978-pip01-10-m01>. (Accessed 6 September 2022).
- [93] Reaman G, Karres D, Ligas F, Lesa G, Casey D, Ehrlich L, et al. Accelerating the global development of pediatric cancer drugs: a call to coordinate the submissions of pediatric investigation plans and pediatric study plans to the European medicines agency and US Food and drug administration. *J Clin Oncol* 2020;38:4227–30.
- [94] Common Commentary - EMA/FDA Common issues requested for discussion by the respective agency (EMA/PDCO and FDA) concerning paediatric oncology development plans (Paediatric Investigation Plans [PIPs] and initial Pediatric Study Plans [iPSPs]). <https://www.fda.gov/media/147197>. (Accessed 6 September 2022).
- [95] Common Commentary - EMA/FDA Common issues requested for discussion by the respective agency (EMA/PDCO and FDA) concerning paediatric oncology development plans (Paediatric Investigation Plans [PIPs] and initial Pediatric Study Plans [iPSPs]). https://www.ema.europa.eu/en/documents/other/common-commentary-ema/fda-common-issues-requested-discussion-respective-agency-ema/pdco-fda-concerning-paediatric-oncology-development-plans-paediatric-investigation-plans-pips_en.pdf. (Accessed 6 September 2022).
- [96] Karres D, Lesa G, Ligas F, Annunen P, van Dartel M, Demolis P, et al. Common Commentary on paediatric oncology drug development. *Ther Innov Regul Sci* 2021. <https://doi.org/10.1007/s43441-021>.
- [97] Georger B, Moertel CL, Whitlock J, McCowage GB, Kieran MW, Broniscer A, et al. Phase I trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN). *J Clin Oncol* 2018;36(15_suppl). 10537-10537.
- [98] de Blank PMK, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, et al. MEK inhibitors for neurofibromatosis type 1 Manifestations: clinical evidence and consensus. *Neuro Oncol* 2022 Jul 5. <https://doi.org/10.1093/neuonc/noac165>.
- [99] Robison N, Pauly J, Malvar J, Gardner S, Allen J, MacDonald T, et al. LGG-52Binimetinib in children with progressive or recurrent low-grade glioma not associated with neurofibromatosis type 1: initial results from a multi-institutional phase ii study. *Neuro Oncol* 2020;22(Supplement_3). December, Page iii376.
- [100] Murugappan MN, King-Kallimanis BL, Reaman GH, Bhatnagar V, Horodniceanu EG, Bouchkouj N, et al. Patient-reported outcomes in pediatric cancer Registration trials: a US Food and drug administration perspective. *J Natl Cancer Inst* 2022;114:12–9.
- [101] Meyerheim M, Karamanidou C, Payne S, Garani-Papadatos T, Sander A, Downing J, et al. MyPal-Child study protocol: an observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients. *BMJ Open* 2021;11:e045226.
- [102] Kieran MW, Caron H, Winther JF, Henderson TO, Haupt R, Hjørth L, et al. ACCELERATE Long-Term Follow-Up Working Group. A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence. *Pediatr Blood Cancer* 2021 Jul;68:e29047.
- [103] Eckstein OS, Allen CE, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, et al. Phase II study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: arm E of the NCI-COG pediatric MATCH trial. *J Clin Oncol* 2022;40:2235–45.
- [104] Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. *Lancet Oncol* 2022;23:53–64.
- [105] Gross AM, Frone M, Gripp KW, Gelb BD, Schoyer L, Schill L, et al. Advancing RAS/RASopathy therapies: an NCI-sponsored intramural and extramural collaboration for the study of RASopathies. *Am J Med Genet* 2020;182:866–76.
- [106] A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma - <https://clinicaltrials.gov/ct2/show/NCT03871257>. (Accessed 6 September 2022).
- [107] A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma. <https://clinicaltrials.gov/ct2/show/NCT04166409>. (Accessed 6 September 2022).
- [108] Pediatric Low Grade Glioma – MEKInhibitor TRial vs Chemotherapy (PLGG - MEKTRIC). <https://clinicaltrials.gov/ct2/show/NCT05180825> (Accessed 6 September 2022).
- [109] A Study to Evaluate DAY101 in Pediatric and Young Adult Patients with Relapsed or Progressive Low-Grade Glioma (FIREFLY-1). <https://clinicaltrials.gov/ct2/show/NCT04775485>. (Accessed 6 September 2022).
- [110] A Study to Compare Treatment with the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma - <https://clinicaltrials.gov/ct2/show/NCT04576117>. (Accessed 6 September 2022).
- [111] Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) - <https://clinicaltrials.gov/ct2/show/NCT03155620>. (Accessed 6 September 2022).
- [112] Phase III Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors. <https://clinicaltrials.gov/ct2/show/NCT02285439>. (Accessed 6 September 2022).
- [113] SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults with Low-Grade Glioma- <https://clinicaltrials.gov/ct2/show/NCT04923126>. (Accessed 6 September 2022).

- [114] Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas (PNOC021) - <https://clinicaltrials.gov/ct2/show/NCT04485559>. (Accessed 6 September 2022).
- [115] DAY101 in Gliomas and Other Tumors. <https://clinicaltrials.gov/ct2/show/NCT03429803>. (Accessed 6 September 2022).
- [116] Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma. <https://clinicaltrials.gov/ct2/show/NCT01089101>. (Accessed 6 September 2022).
- [117] Sorafenib in Children and Young Adults with Recurrent or Progressive Low-Grade Astrocytomas. <https://clinicaltrials.gov/ct2/show/NCT01338857>. (Accessed 6 September 2022).
- [118] Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Subjects with Cancers Harboring V600 Mutations. <https://clinicaltrials.gov/ct2/show/NCT02124772>. (Accessed 6 September 2022).